NASDAQ:APLT

Applied Therapeutics - APLT Stock Forecast, Price & News

$0.81

+0.01 (+1.25%)

(As of 03/31/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.76
▼
$0.85
50-Day Range: $0.80
▼
$1.21
52-Week Range: $0.50
▼
$2.73

Volume: 202,050 shs
Average Volume: 292,727 shs
Market Capitalization: $39.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.13

Institutional Ownership

Applied Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 1,184.3% Upside
$10.42 Price Target
Short Interest: Healthy
0.87% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.88
Upright™ Environmental Score
News Sentiment: 0.94
Based on 4 Articles This Week
Insider Trading: Selling Shares
$19,950 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

116th out of 1,004 stocks

Pharmaceutical Preparations Industry

44th out of 489 stocks

3.3

Analyst's Opinion

Consensus Rating
Applied Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.42, Applied Therapeutics has a forecasted upside of 1,184.3% from its current price of $0.81.
Amount of Analyst Coverage
Applied Therapeutics has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.87% of the outstanding shares of Applied Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Applied Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Applied Therapeutics has recently decreased by 17.28%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Applied Therapeutics does not currently pay a dividend.
Dividend Growth
Applied Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Applied Therapeutics has received a 74.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Applied Therapeutics is -0.88.

2.7

News and Social Media Coverage

News Sentiment
Applied Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Applied Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 22 people have searched for APLT on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Applied Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Applied Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,950.00 in company stock.
Percentage Held by Insiders
17.00% of the stock of Applied Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
62.94% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Applied Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Applied Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Applied Therapeutics has a P/B Ratio of 10.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Applied Therapeutics (NASDAQ:APLT) Stock

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Receive APLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLT Stock News Headlines

March 31, 2023 | americanbankingnews.com

Applied Therapeutics, Inc. (NASDAQ:APLT) Sees Significant Decline in Short Interest

March 23, 2023 | finance.yahoo.com

Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results

April 1, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.

March 18, 2023 | finance.yahoo.com

Quite a few insiders invested in Applied Therapeutics, Inc. (NASDAQ:APLT) last year which is positive news for shareholders

March 1, 2023 | finance.yahoo.com

Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

February 24, 2023 | finance.yahoo.com

Applied Therapeutics Reveals Pivotal Study Data In Hereditary Neuropathy

February 16, 2023 | msn.com

Applied Therapeutics rises ~10% as AT-007 shows efficacy in phase 3 trial for muscle disorder

February 16, 2023 | finance.yahoo.com

Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency

April 1, 2023 | Legacy Research (Affiliate) (Ad)

"Prepare for Five Years of Famine"

Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast.

February 9, 2023 | finance.yahoo.com

Applied Therapeutics to Present at the SVB Securities Global Biopharma Conference

January 21, 2023 | forbes.com

Applied Therapeutics

January 4, 2023 | msn.com

Why Applied Therapeutics Shares Are Seeing Blue Skies

January 4, 2023 | uk.finance.yahoo.com

Applied Therapeutics, Inc. (APLT)

November 9, 2022 | finance.yahoo.com

Applied Therapeutics Reports Third Quarter 2022 Financial Results

October 31, 2022 | finance.yahoo.com

Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022

October 25, 2022 | finance.yahoo.com

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

October 9, 2022 | finance.yahoo.com

Insiders who purchased Applied Therapeutics, Inc. (NASDAQ:APLT) earlier this year lose an additional US$86k as the stock sinks to US$0.62

October 6, 2022 | marketwatch.com

Applied Therapeutics Down 33% on Clinical Trial Update

October 6, 2022 | finance.yahoo.com

Applied Therapeutics' Lead Candidate Pediatric Study Failed To Reach Statistical Significance

October 6, 2022 | markets.businessinsider.com

Applied Therapeutics: AT-007 Trial Shows Positive Data Trend; Yet To Reach Statistical Significance

October 6, 2022 | finance.yahoo.com

Applied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format

September 2, 2022 | finance.yahoo.com

Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now

August 16, 2022 | nasdaq.com

We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate

August 12, 2022 | msn.com

Recap: Applied Therapeutics Q2 Earnings

August 12, 2022 | finance.yahoo.com

Applied Therapeutics Reports Second Quarter 2022 Financial Results

July 28, 2022 | finance.yahoo.com

Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference

June 23, 2022 | markets.businessinsider.com

Nasdaq Jumps Over 100 Points; Applied Therapeutics Shares Plummet

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive APLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLT Company Calendar

Last Earnings: 3/23/2023
Today: 4/01/2023
Next Earnings (Estimated): 5/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APLT
CUSIP: N/A
CIK: 1697532
Web: www.appliedtherapeutics.com
Phone: (212) 220-9226
Fax: N/A
Employees: 34
Year Founded: 2017

Price Target and Rating

Average Stock Price Forecast: $10.42
High Stock Price Forecast: $23.00
Low Stock Price Forecast: $2.25
Forecasted Upside/Downside: +408.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.40)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-82,510,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -383.75%
Return on Assets: -131.25%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.12
Quick Ratio: 1.12

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.08 per share
Price / Book: 10.14

Miscellaneous

Outstanding Shares: 48,110,000
Free Float: 39,935,000
Market Cap: $39.02 million
Optionable: Not Optionable
Beta: 1.90

Social Links

Key Executives

Shoshana Shendelman
Chairman, President, CEO & Secretary

Steven Ortega
Chief Financial & Accounting Officer

Riccardo Perfetti
Chief Medical Officer

Adam Hansard
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APLT Stock - Frequently Asked Questions

Should I buy or sell Applied Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" APLT shares.
View APLT analyst ratings or view top-rated stocks.
What is Applied Therapeutics' stock price forecast for 2023?: 2 equities research analysts have issued twelve-month target prices for Applied Therapeutics' shares. Their APLT share price forecasts range from $2.25 to $23.00. On average, they predict the company's share price to reach $10.42 in the next year. This suggests a possible upside of 1,184.3% from the stock's current price.
View analysts price targets for APLT or view top-rated stocks among Wall Street analysts.
How have APLT shares performed in 2023?: Applied Therapeutics' stock was trading at $0.76 at the beginning of the year. Since then, APLT shares have increased by 6.7% and is now trading at $0.8111.
View the best growth stocks for 2023 here.
Are investors shorting Applied Therapeutics?: Applied Therapeutics saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 417,000 shares, a drop of 17.3% from the February 28th total of 504,100 shares. Based on an average daily volume of 279,900 shares, the days-to-cover ratio is presently 1.5 days.
View Applied Therapeutics' Short Interest.
When is Applied Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our APLT earnings forecast.
How were Applied Therapeutics' earnings last quarter?: Applied Therapeutics, Inc. (NASDAQ:APLT) released its quarterly earnings results on Thursday, March, 23rd. The company reported ($0.16) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Applied Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), Walt Disney (DIS) and Raytheon Technologies (RTX).
When did Applied Therapeutics IPO?: (APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank acted as the underwriters for the IPO and Baird was co-manager.
What is Applied Therapeutics' stock symbol?: Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."
How do I buy shares of Applied Therapeutics?: Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Applied Therapeutics' stock price today?: One share of APLT stock can currently be purchased for approximately $0.81.
How much money does Applied Therapeutics make?: Applied Therapeutics (NASDAQ:APLT) has a market capitalization of $39.02 million. The company earns $-82,510,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.
How can I contact Applied Therapeutics?: Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The official website for the company is www.appliedtherapeutics.com. The company can be reached via phone at (212) 220-9226 or via email at maeve@argotpartners.com.

This page (NASDAQ:APLT) was last updated on 4/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Applied Therapeutics - APLT Stock Forecast, Price & News

Applied Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Applied Therapeutics (NASDAQ:APLT) Stock

APLT Stock News Headlines

APLT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

APLT Stock - Frequently Asked Questions

Overall MarketRank^™